Menu
Recruiting NCT03826992

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Phase I Interventional Leukemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vyxeos, Venetoclax.
Who it may be relevant to
Registry conditions: Leukemia. Basic parameters: 1 year — 39 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia

Overview

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.

Detailed description

This is a single-institution Phase I pilot study designed to test the safety and tolerability of combining venetoclax with Vyxeos (CPX-351, cytarabine and daunorubicin liposome) for the treatment of relapsed/refractory acute leukemia in young patients. Subjects will receive a single course of study therapy consisting of daily, oral or crushed venetoclax at an assigned dose level with a 3-day ramp-up to target dose and Vyxeos administered intravenously at the established dose on Days 1, 3, and 5. In addition to safety and tolerability, the overall response rate to these therapies will be estimated. Pharmacokinetic (PK) analysis will also be conducted to define the drug clearance of venetoclax in this combination.

Interventions

  • Drug Vyxeos
    Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
  • Drug Venetoclax
    Venetoclax Dose: 1. Dose Level 0 - weight based daily dosing for 21 days 2. Dose Level -1 - weight based daily dosing for 14 days 3. Dose Level -2- weight based daily dosing for 10 days 4. Dose Level -3- weight based daily dosing for 7 days

Primary outcome measures

  • Feasibility of combining venetoclax and Vyxeos (dose limiting toxicities) [Time frame: 28 days]
  • Treatment related toxicities [Time frame: 60 days]
Secondary outcome measures (2)
  • Disease response [Time frame: 42 days]
  • Cancer therapeutics-related cardiac dysfunction (CTRCD) in patients who have previously received anthracyclines [Time frame: 60 days]

Eligibility criteria

Inclusion criteria

  • Ages 1 Year to 39 Years
  • Diagnosis of one of the following:
  • Acute myeloid leukemia (AML), any subtype except
  • Patients with acute promyelocytic leukemia (APML) are NOT eligible
  • Patients with ML-DS are NOT eligible
  • Myeloid sarcoma
  • Acute leukemia of ambiguous lineage (ALAL)
  • Acute undifferentiated leukemia (AUL)
  • T/myeloid mixed phenotype acute leukemia (MPAL)
  • B/myeloid MPAL
  • MPAL with KMT2A-rearrangement MPAL with t (9;22) are NOT eligible
  • T-cell acute lymphoblastic leukemia (T ALL)
  • Early thymocyte precursor (ETP) ALL
  • KMT2A-rearranged ALL
  • Disease Status
  • Relapsed/Refractory AML, MPA, and AUL
  • Untreated therapy related AML
  • Relapsed/Refractory KMT2A-rearranged ALL, T-cell ALL, ETEP ALL
  • Karnofsky/Lanksy performance level score of greater than or equal to 50 percent.
  • Prior therapy requirements
  • Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant (HSCT) or Anthracycline Exposure
  • 14 days must have elapsed since the completion of systemic cytotoxic therapy other than hydroxyurea, decitabine or azacitidine
  • 2 weeks must have elapsed for local palliative radiotherapy (RT); 6 months must have elapsed if prior craniospinal RT or if 50% radiation of pelvis, and at least 6 weeks must have elapsed if other substantial bone marrow radiation
  • Adequate renal, liver, cardiac, and central nervous system (CNS) function

Exclusion criteria

  • Diagnosis of one of the following:
  • Myeloid Leukemia associated with Down Syndrome (ML-DS)
  • Acute Promyelocytic Leukemia (APML)
  • Acute leukemia with CNS status 3 involvement
  • Philadelphia chromosome t(9;22) positive leukemia (Ph+ ALL, AML, MPAL, or AUL)
  • Fanconi Anemia, Shwachman-Diamond syndrome, or any other bone marrow failure syndrome or DNA repair disorder
  • Wilson's Disease or other copper-metabolism disorder
  • Pregnant or breastfeeding
  • Uncontrolled infection
  • Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum
  • Receipt of growth factors within 7 days prior to enrollment
  • Currently receiving another investigational drug
  • Currently receiving anti-cancer agents (with the exception of intrathecal (IT) agents or hydroxyurea)
  • Unable to comply with the safety monitoring requirements of the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Cincinnati Children's Hospital Medical Center — Cincinnati

Identifiers

NCT: NCT03826992 · V2-MA-1801

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗